Introduction/Background Standard therapy for recurrent endometrial cancer is chemotherapy. There is less conclusive evidence about surgical treatment of recurrent endometrial cancer. We investigated outcomes after surgical treatment for recurrent endometrial cancer at our hospital and verified its effectiveness.

Methodology We reviewed the medical records retrospectively for patients who underwent surgical treatment for primary recurrent endometrial cancer between September 2002 and March 2016.

We evaluated clinicopathological characteristics, time to recurrence, age at the time of surgical treatment for recurrence, the site of recurrence, residual tumor and postoperative therapy of recurrent surgery, progression-free survival (PFS) and overall survival (OS).

Results 18 patients were evaluated. The median follow-up was 28.9 months (12.7–134.2).

Median age was 65.5 (48–78) years old. The site of recurrence were lung 7, peritoneal dissemination 7, and lymph nodes 5. 14 of 18 patients had underwent macroscopic complete tumor resection. Median PFS was 18.1 months (0.9–134.2) and median OS was 119.1 months (31.1–189.2).Prognostic factors for surgical treatment of PFS were lung metastases (HR 0.18 [95% CI: 0.042–0.77], P<0.05), age at the time of surgical treatment for recurrence (66 years or older) (HR 0.25 [95% CI: 0.07–0.95], P<0.05), and those of OS were residual tumor (HR 10.6 [95% CI: 1.69–66.9], P<0.05), time to recurrence(758 days or more) (HR 0.12 [95% CI: 0.02–0.80], P<0.05).

Conclusion Surgical treatment of recurrent endometrial cancer may be effective for patients who had longer time to recurrence and underwent macroscopic complete tumor resection.

Disclosure Nothing to disclose.